Chemotherapy for cholangiocarcinoma: An update

Area of Science:

• Oncology
• Gastroenterology

Background:

• Cholangiocarcinomas (bile duct cancers) are aggressive malignancies with poor prognosis.
• Current 5-year survival rates range from 5%-10%, with 25%-30% for surgically resectable cases.
• Optimizing adjuvant strategies is essential to improve cure rates after surgery.

Purpose of the Study:

• To review current treatment strategies for cholangiocarcinoma.
• To evaluate the role of adjuvant therapy and systemic treatments.
• To highlight the importance of clinical trials for improving patient outcomes.

Main Methods:

• Review of relevant studies, including Japanese trials, ESPAC-3, BILCAP, and meta-analyses.
• Analysis of current medical oncology guidelines for adjuvant therapy.
• Discussion of treatment options for locally advanced and metastatic cholangiocarcinoma.

Main Results:

• Postoperative adjuvant therapy is recommended for positive resection margins or node-positive disease.
• Chemoradiation may prolong survival and manage symptoms in unresectable cases.
• Gemcitabine plus cisplatin/oxaliplatin is a superior first-line regimen for metastatic disease.

Conclusions:

• Individualized, multidisciplinary management is critical for cholangiocarcinoma patients.
• Further research and clinical trials are needed to define optimal adjuvant and systemic therapies.
• Enrollment in clinical trials is strongly recommended for patients with advanced or metastatic disease.